Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB

Wednesday, March 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the positive results of ALG-000184 combined with ETV, demonstrating stronger antiviral effects compared to ETV alone in patients with HBeAg-positive chronic hepatitis B (CHB). This combination therapy may offer a more effective treatment option for this patient population, highlighting its potential in clinical settings.
Price reaction · baseline $24.5275 (2024-03-27T17:41:00.000Z) · hit during market hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Combination therapy shows stronger antiviral effects.
  • Potential for improved treatment in HBeAg-positive CHB patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a therapeutic agent being studied for its antiviral effects in chronic hepatitis B.

How does ALG-000184 compare to ETV?

ALG-000184 combined with ETV shows stronger antiviral effects than ETV alone.

Who benefits from ALG-000184 treatment?

Patients with HBeAg-positive chronic hepatitis B may benefit from ALG-000184.

What are the implications of this study?

The study suggests that ALG-000184 could enhance treatment options for chronic hepatitis B.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 ETV HBeAg-positive chronic hepatitis B antiviral therapy
Last updated: Mar 27, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →